schizandrin b has been researched along with Acute Lung Injury in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Han, J; Huang, L; Huh, JY; Ji, L; Liang, G; Luo, W; Pavlov, VN; Samorodov, AV; Wang, Y; Yang, D; Yin, L; Zhang, Q; Zhu, W; Zhuang, Z | 1 |
| Bian, H; Cai, J; Cai, Z; Liu, J; Zhu, G | 1 |
2 other study(ies) available for schizandrin b and Acute Lung Injury
| Article | Year |
|---|---|
Schisandrin B protects against LPS-induced inflammatory lung injury by targeting MyD88.
Topics: Acute Lung Injury; Animals; Anti-Inflammatory Agents; Lignans; Lipopolysaccharides; Mice; Myeloid Differentiation Factor 88; NF-kappa B; Toll-Like Receptor 4 | 2023 |
Suppression of P2X7/NF-κB pathways by Schisandrin B contributes to attenuation of lipopolysaccharide-induced inflammatory responses in acute lung injury.
Topics: Acute Lung Injury; Animals; Anti-Inflammatory Agents; Bronchoalveolar Lavage Fluid; Cyclooctanes; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Lignans; Lipopolysaccharides; Lung; Male; Mice, Inbred BALB C; NF-kappa B; Polycyclic Compounds; Receptors, Purinergic P2X7; Signal Transduction | 2016 |